Original language | English (US) |
---|---|
Pages (from-to) | 1531-1533 |
Number of pages | 3 |
Journal | JAMA Internal Medicine |
Volume | 180 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2020 |
Externally published | Yes |
ASJC Scopus subject areas
- Internal Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA Internal Medicine, Vol. 180, No. 11, 11.2020, p. 1531-1533.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Representation of Older Adults in Cardiovascular Disease Trials since the Inclusion across the Lifespan Policy
AU - Nanna, Michael G.
AU - Chen, Sean T.
AU - Nelson, Adam J.
AU - Navar, Ann Marie
AU - Peterson, Eric D.
N1 - Funding Information: Author Contributions: Dr Nanna had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Acquisition, analysis, or interpretation of data: Nanna, Chen, Nelson, Navar. Drafting of the manuscript: Nanna, Chen. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Nanna. Administrative, technical, or material support: Chen, Peterson. Supervision: Nanna, Navar, Peterson. Conflict of Interest Disclosures: Dr Nanna reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Navar reported receiving personal fees from Amgen, AstraZeneca, Janssen, Esperion, Amarin, Sanofi, Regeneron, Novo Nordisk, Novartis, The Medicines Company, and Pfizer and grants from Amgen, Janssen, Amarin, Sanofi, and Regeneron outside the submitted work. Dr Peterson reported receiving grants from Amgen, Sanofi, AstraZeneca, Merck, and Janssen and personal fees from Amgen, AstraZeneca, Merck, Novartis, Pfizer, Janssen, and Sanofi outside the submitted work. No other disclosures were reported. Funding/Support: This study was supported by training grant T32-HL069749 from the National Institutes of Health (Dr Nanna) and grant NIH K01HL133416-01 from the National Institutes of Health (Dr Navar). Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 1. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26(7): 783-790. doi:10.1007/s11606-010-1629-x 2. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med. 2014;174(11):1868-1870. doi:10. 1001/jamainternmed.2014.4758 3. Tinetti ME. The gap between clinical trials and the real world: extrapolating treatment effects from younger to older adults. JAMA Intern Med. 2014;174(3): 397-398. doi:10.1001/jamainternmed.2013.13283 4. Bernard MA, Clayton JA, Lauer MS. Inclusion across the lifespan: NIH policy for clinical research. JAMA. 2018;320(15):1535-1536. doi:10.1001/jama.2018.12368 5. National Institutes of Health. Revision: NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects. National Institutes of Health; 2017. Notice NOT-OD-18-116. Accessed March 9, 2020. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-116.html Funding Information: Funding/Support: This study was supported by grants from the Agency for Healthcare Research and Quality (K01HS026727) and the University of Pittsburgh Pepper Older Americans Independence Center (subaward from National Institute on Aging grant P30 AG024827-13).
PY - 2020/11
Y1 - 2020/11
UR - http://www.scopus.com/inward/record.url?scp=85090961469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090961469&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2020.2750
DO - 10.1001/jamainternmed.2020.2750
M3 - Letter
C2 - 32897289
AN - SCOPUS:85090961469
SN - 2168-6106
VL - 180
SP - 1531
EP - 1533
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
IS - 11
ER -